GB2388114A - Methods of diagnosis or prognosis of a BRCA associated disorder - Google Patents
Methods of diagnosis or prognosis of a BRCA associated disorder Download PDFInfo
- Publication number
- GB2388114A GB2388114A GB0308377A GB0308377A GB2388114A GB 2388114 A GB2388114 A GB 2388114A GB 0308377 A GB0308377 A GB 0308377A GB 0308377 A GB0308377 A GB 0308377A GB 2388114 A GB2388114 A GB 2388114A
- Authority
- GB
- United Kingdom
- Prior art keywords
- brca
- gene
- disorder
- interaction
- gene product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 61
- 238000003745 diagnosis Methods 0.000 title claims abstract description 9
- 238000004393 prognosis Methods 0.000 title claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 87
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 72
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 56
- 230000003993 interaction Effects 0.000 claims abstract description 38
- 241001465754 Metazoa Species 0.000 claims abstract description 32
- 101150115162 p27 gene Proteins 0.000 claims abstract description 15
- 230000009261 transgenic effect Effects 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 7
- 102100036659 26S proteasome non-ATPase regulatory subunit 9 Human genes 0.000 claims description 71
- 101150073031 cdk2 gene Proteins 0.000 claims description 36
- 230000000694 effects Effects 0.000 claims description 35
- 206010006187 Breast cancer Diseases 0.000 claims description 29
- 208000026310 Breast neoplasm Diseases 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 21
- 108700028369 Alleles Proteins 0.000 claims description 17
- 210000001519 tissue Anatomy 0.000 claims description 14
- 230000035772 mutation Effects 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 102000036365 BRCA1 Human genes 0.000 claims description 5
- 108700020463 BRCA1 Proteins 0.000 claims description 5
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 claims description 5
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 5
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 101700002522 BARD1 Proteins 0.000 claims description 3
- 102100028048 BRCA1-associated RING domain protein 1 Human genes 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 102100027240 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Human genes 0.000 claims description 3
- 101710137278 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 101710199392 TATA-box-binding protein 1 Proteins 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 210000000867 larynx Anatomy 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000011820 transgenic animal model Methods 0.000 claims description 3
- 101100495324 Caenorhabditis elegans cdk-7 gene Proteins 0.000 claims description 2
- 101150092630 Myt1 gene Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 abstract description 27
- 102000051618 BRCA1-associated protein Human genes 0.000 abstract description 11
- 108700039023 BRCA1-associated protein Proteins 0.000 abstract description 11
- 208000035475 disorder Diseases 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 14
- 102000016736 Cyclin Human genes 0.000 description 12
- 108050006400 Cyclin Proteins 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 101150072950 BRCA1 gene Proteins 0.000 description 10
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000005557 antagonist Substances 0.000 description 9
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000022131 cell cycle Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 102000003909 Cyclin E Human genes 0.000 description 6
- 108090000257 Cyclin E Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- -1 cam Proteins 0.000 description 5
- 230000011360 lung alveolus development Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001351 cycling effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000052609 BRCA2 Human genes 0.000 description 3
- 108700020462 BRCA2 Proteins 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 102000000578 Cyclin-Dependent Kinase Inhibitor p21 Human genes 0.000 description 3
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000000668 oral spray Substances 0.000 description 2
- 229940041678 oral spray Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 101150072531 10 gene Proteins 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000002428 Cyclin C Human genes 0.000 description 1
- 108010068155 Cyclin C Proteins 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102100033269 Cyclin-dependent kinase inhibitor 1C Human genes 0.000 description 1
- 101710153652 Cyclin-dependent kinase inhibitor 1C Proteins 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 230000037057 G1 phase arrest Effects 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000914680 Homo sapiens Fanconi anemia group C protein Proteins 0.000 description 1
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 102100040443 Keratin, type I cytoskeletal 15 Human genes 0.000 description 1
- 108010066330 Keratin-15 Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010014691 Lithostathine Proteins 0.000 description 1
- 102100027361 Lithostathine-1-alpha Human genes 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- DGQLVPJVXFOQEV-JNVSTXMASA-N carminic acid Chemical compound OC1=C2C(=O)C=3C(C)=C(C(O)=O)C(O)=CC=3C(=O)C2=C(O)C(O)=C1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DGQLVPJVXFOQEV-JNVSTXMASA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000008176 mammary development Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/02—Cells from transgenic animals
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Methods of treating a BRCA associated disorder, particularly a BRCA1 associated cancer. The invention also provides a method of diagnosis or prognosis of the disorder, preferably a BRCA-1 associated cancer and methods of determining suitable treatment regimes for the disorder or cancer. The invention also provides a transgenic animal useful as a model for testing potential therapeutics for the disorder or cancer. In a first aspect of the present invention there is provided a method of treating a BRCA associated disorder, said method comprising modulating interaction between a BRCA gene or gene product and a p27 gene or gene product.
Description
23881 1 4
METHODS OF DIAGNOSIS OR PROGNOSIS OF A BRCA ASSOCIATED
DISORDER
The invention relates to a method of diagnosis or prognosis of a BRCA 5 associated disorder, preferably a BRCA-1 associated cancer, methods of determining suitable treatment regimes for the disorder or cancer and to methods of treating a BRCA associated disorder, particularly a BRCA-1 associated cancer. The invention also provides a transgenic animal useful as a model for testing potential therapeutics for the disorder or cancer.
BACKGROUND
Proteins encoded by the breast cancer susceptibility genes (BRCA proteins) have been implicated in a predisposition to breast, ovarian and other cancers.
15 These proteins are ubiquitously expressed thereby implicating them in many processes fundamental to all cells including ONA repair and recombination, checkpoint control of cell cycle and transcription.
Specifically, genetic susceptibility to breast cancer has been linked to mutations 20 of the BRCA-1 and BRCA-2 genes. Proteins encoded by these genes are believed to work to preserve chromosome structure, but their precise role is unclear due to them being involved in a multitude of processes. It is postulated that a mutation causes a disruption in the protein which causes chromosomal instability in BRCA deficient cells thereby predisposing them to neoplastic 25 transformation.
About 10% of breast cancer cases cluster in families, some due to mutations in the BRCA-1 and BRCA-2 genes, giving rise to higher cancer risk. Mutations in other genes linked to tumor suppression may account for cancer predisposition.
30 These include mutations in p53 tumor suppression, the STK11/LKB, protein kinase or the PTEN phosphatase.
Apart from the existence of mutations in tumor suppressor genes, there is no clear picture of how these genes interact which manifests in a predisposition or development of tumours.
5 BRCA1 associated cancers have a unique histopathology and demonstrate more frequent loss of expression of the tumour suppressor protein p27Kip1 than in sporadic cases. p27Kip1 normally plays a role in maintaining G1 arrest -
inhibiting cyclin-CDK complexes and is degraded upon mitogen stimulation to re-enter the cell cycle. p27Kip1 has an accepted role as a tumour suppressor 10 gene and poor prognosis associates with loss of expression in a wide array of cancers. Low p27 levels are commonly seen in many human cancers such as epithelial cancers including, lung cancer, gastrointestinal malignancies, breast cancer, prostate cancer, ovarian cancer, and carcinomas of the larynx and oral cavity.
15 The correlation is not as clear for brain tumours and malignant Iymphomas.
p27, as a prognostic tool has been used for breast cancer. This is the most common solid tumor and one of the most frequent causes of death in women. It has been shown that both low levels of p27 and high levels of cyclin E were 20 independent predictors of overall survival. Patients whose breast cancers showed both low p27 and elevated cyclin E proteins had the highest mortality.
An inverse correlation between cyclin E levels and p27 has also been observed in breast cancers, whereas increased levels of cyclin C)1 were associated with both higher p27 levels and low tumor grade (a greater degree of differentiation) 25 in another study. Accordingly a correlation of p27 and that of cycline is not always a clear and absolute indication of the predisposition for the cancer.
A low level of p27 may influence many cell functions. Because it is actively involved in various stages of the cell cycle and its role in cell progression is 30 complex it may also be associated with apoptosis, differentiation and responses to cellular stresses, such as, but not limited to, DNA damage.
The relevance of p27 to tumor phenotypes provides some guidance as to pathways regulating its interaction with other molecules within the cell. A direct
( 3 correlation of the p27 levels to the cancer has not been made and it is unclear whether such a correlation does exist particularly when p27 is involved in many stages of the cell cycle. The action of p27 is not clearly understood. Its importance however may lead to the generation of new and effective drugs for 5 cancer. A specific target which can be used to produce the effective drug remains elusive.
Accordingly, it is an object of the present invention to identify a suitable target of a BRCA associated disorders, especially a BRCA-1 associated disorder such 10 as a cancer, more preferably a breast cancer which may be used to develop useful and effective drugs for cancer treatment.
SUMMARY OF THE INVENTION
15 In a first aspect of the present invention there is provided a method of diagnosis or prognosis of a BRCA associated disorder in a tissue suspected of the disorder, said method comprising determining an interaction between a BRCA gene or gene product and a p27 gene or gene product and comparing the interaction against the interaction in a tissue that is absent the disorder.
The method of diagnosis or prognosis may be conducted in vitro.
The interaction may be in the tissue suspected of the disorder.
25 Applicants have found for the first time that the loss of p27 protein is functionally important in the progression of BRCA associated cancers. Whilst p27 levels have been found to be low in various cancers, evidence of a causal link between the two has not previously been shown to have an effect in establishing or reversing the phenotype.
In a preferred embodiment the method involves determining an interaction between a BCRA gene or gene product and a p27 gene or gene product where the interaction is a modulation or change of the expression andlor activity of a
( 4 cdk2 protein, preferably determining a reduction in the expression and/or activity of the cdk2 protein.
Applicants have found that by specific targeting of cdk2 and reducing the 5 activity of this kinase, the BRCA associated disorder may be treated. It is postulated that p27 would inhibit cdk2. Low levels of p27 in cancer fails to inhibit cdk2 and hence cell cycling and proliferation in cancers is not inhibited.
In a further preferred aspect of the invention, there is provided a method of 10 treating a BRCA associated disorder in a patient, said method comprising administering a therapeutically effective amount of a cdk-2 inhibitor or antagonist to the patient.
In yet another aspect of the present invention, there is provided a transgenic 15 non-human animal model for breast cancer wherein said animal shows a clinical interaction between BRCA and p27 said animal comprising a promoter-driven dominant negative BRCA allele.
The animal model may be a rodent, preferably a mouse.
In yet another aspect of the present invention, there is provided a method of screening potential therapeutic compounds for treatment of BRCA associated disorder, said method comprising: inducing a BRCA associated disorder phenotype in a transgenic animal 25 model for the BRCA associated disorder, said animal comprising a promoter driven dominant negative BRCA allele; exposing a potential therapeutic compound to the transgenic animal; and noting a change in the phenotype, and selecting therapeutic compounds on the basis of a positive change in phenotype.
FIGURES
Figure 1 shows a reduction in the dosage of p27kiP' alters the phenotype in MMTV-trBRCA-1 expressing mice.
( 5 Figure 2 shows MMTV-trBRCA-1 and reduced p27 dosage interact during both alveolar development and ductal branching.
5 Figure 3 shows that a reduced dosage of p27 does not reduce the expression of the MMlV-trBRCA-1 transgene.
Figure 4 shows staining for p27kiP' corresponds to regions with low proliferation.
10 Figure 5 shows an analysis of primary mammary epithelia cells (PMECS) from transgenic mice.
DESCRIPTION OF THE INVENTION
15 In a first aspect of the present invention there is provided a method of treating a BRCA associated disorder, said method comprising modulating interaction between a BRCA gene or gene product and a p27 gene or gene product.
In another aspect of the present invention, there is provided a method of 20 diagnosis or prognosis of a BRCA associated disorder in a tissue suspected of the disorder, said method comprising determining an interaction between a BRCA gene or gene product and a p27 gene or gene product and comparing the interaction against the interaction in a tissue that is absent the disorder.
25 Applicants have found for the first time that the loss of p27 protein is functionally important in the progression of BRCA associated cancers. Whilst p27 levels have been found to be low in various cancers, evidence of a causal link between the two has not previously been shown to have an effect in establishing or reversing the phenotype.
As used herein, a 4BRCA associated disorder" is a disorder associated with a BRCA protein, preferably a BRCA-1 or related proteins including BAP-1 and BARD1; or BRCA-2 protein encoded by a mutated BRCA gene. Preferably the disorder is associated with a mutated BRCA-1 or BRCA-2 gene. The disorder
! 6 may manifest as a cancer, preferably an epithelial cancer including but not limited to lung cancer, gastrointestinal malignancies, breast cancer, prostate cancer, ovarian cancer and carcinomas of the larynx and oral cavity. More preferably the cancer is a breast or ovarian cancer. Most preferably, it is a 5 breast cancer.
Treatment as used herein includes in its broadest sense to include prophylactic (is preventative), prognostic or diagnostic treatment as well as treatments designed to ameliorate the effects of the disorder. The treatment 10 may be aimed at the disorder or at the effects of the disorder. Additionally, treatment may include reversing phenotypes characteristic of the disorder.
A cell may show a predisposition or propensity for a BRCA associated disorder, by identification of prognostic markers, including but no limited to, oncogenes or 15 genes which are indicative of the cancer such as mutations of the BRCA gene including mutations of the BRCA-1 or BRCA-2 tumor suppression genes.
Preferably, the BRCA associated disorder coincides with low levels of p27.
Cancers showing low levels of p27 include the epithelial cancers described 20 above. Preferably, the cells are BRCA1 or BRCA2 negative or include mutated BRCA-1 or related proteins including BAP-1 or BARD-1 or mutated BRCA-2 protein. Preferably the cells of the cancers show mutated BRCA genes, more preferably mutated BRCA-1 or BRCA-2 genes indicating, a predisposition for breast cancer.
It is preferred that to treat the BRCA associated disorder, an increased interaction between the BRCA gene or gene product with a p27 gene or gene product is induced. These may be achieved by increasing the p27 protein which is low in BRCA associated disorders. Similarly. In a tissue that has a 30 propensity for the BRCA associated disorder, there would be an increased interaction between the BRCA gene or gene product and a p27 gene or gene product. This increased interaction can be compared against normal tissue that does not have the BRCA associated disorder.
Applicants have found that loss of p27 protein is functionally important in the progression of BRCA-1 associated cancers. Hence, increased p27 protein may reverse the effects of BRCA-1 mutations and a predisposition to cancer.
5 As used herein "modulating interaction" is meant to describe a change in interaction between at least two integers. Modulating" may include direct or indirect modulation. Direct modulation acts directly on the integers involved whilst indirect modulation acts indirectly by targeting downstream or upstream parameters that may affect the integrity of the integers thereby changing the 10 manner in which they may interact.
The "BRCA gene and gene products" as referred herein is preferably a BRCA1 or BRCA-2 gene or gene product.
15 The "p27 gene or gene products" as referred herein is preferably the p27kiP' gene or gene product.
The method of treatment may be performed by introducing a compound which modulates an interaction between BCRA gene and gene products and p27 20 gene and gene products to a site of the BRCA associated disorder. For instance, if the disorder is a cancer, such modulators may be directly injected into the tumor or if the cancer is more wide spread, the compound my be introduced by injection either subcutaneously, intravenously, intraperitoneally, intradermally, intramuscularly, mucosally or any combination of these. The 25 compound may be injected in soluble fomm, aggregate form, attached to a physical carrier or mixed with an adjuvant, using methods and materials known-
in the art.
Throughout the description and claims of this specification, the word "comprise"
30 and variations of the word, such as "comprising" and "comprises, is not intended to exclude other additives, components, integers or steps.
In a preferred embodiment the method involves modulating interaction between a BCRA gene or gene product and a p27 gene or gene product by modulating
(- 8 expression and/or activity of a cdk2 protein, preferably reducing the expression and/or activity of the cdk2 protein.
In another preferred aspect, the invention provides a method of diagnosis or 5 prognosis of a BRCA associated disorder in a tissue suspected of the disorder wherein the interaction between the BRCA gene or gene product and the p27 gene or gene product is an interaction that is modulated by modulating expression and/or activity of a cdk-2 protein.
10 Cell cycle progression is governed by cyclin dependent kineses (cdks) that are activated by cyclin binding and inhibited by the cdk inhibitors. The cdks regulate biochemical pathways, or check-points, that integrate mitogenic and growth-inhibitory signals and coordinate cell-cycle transitions. Passage through G1 into S phase is regulated by the activities of cyclin D-, cyclin E-, and cyclin 15 A-associated cdks. Btype cyclin associated kineses regulate the G2/M transition. Members of the kinase inhibitor protein (km) family, p21KiP', p27KiP', and p57Kip2, bind and inhibit cyclin-bound cdks. Although p21 and p27 are inhibitors of 20 cyclin E/cdk2, they may also function in the assembly and activation of cyclin D-
cdk4 and -cdk6 complexes.
The cdk inhibitor p27 acts in GO and early G1 to inhibit G1 cyclin cdks, with the target generally being E-type cyclin/cdk2 complexes. Mitogenic growth factor 25 signalling causes loss of p27, and p27 levels and/or activity increase in response to different signals. p27 mRNA levels are constant throughout the cell cycle and p27 protein levels are regulated by translational controls by ubiquitin-
mediated proteolysis.
30 Without being limited by theory, this method utilises the discovery that the activity of cdk2 is important in maintaining the phenotype and progression of the BRCA associated disorder, preferably in cancer, most preferably in breast cancer. By reducing the activity of cdk2 or inhibiting cdk2, selective toxicity for
cancers, particularly breast cancer, more particularly a BRCA1 mutant breast cancer can be applied to reduce cell cycling and progression of the phenotype.
The protein cdk2 is closely involved in cell cycle progression. However, it is not 5 the only cyclin dependent kinase involved. Other cyclin dependent kineses include cdk4 and cdk6 activity involved in specific stages of the cell cycle. In particular these cyclin dependent kineses are involved in the G1 phase whereas cdk2 can be involved in the G0/G1/S phase. The activity of these kineses may be regulated by binding of the cycling, by phosphorylation and by negative 10 regulators or cdk inhibitors such as p15, p16, p18, p19, p21, p27 and p57.
Applicants have found that by specific targeting of cdk2 and reducing the activity of this kinase, the BRCA associated disorder may be treated. It is postulated that p27 would inhibit cdk2. Low levels of p27 in cancer fails to 15 inhibit cdk2 and hence cell cycling and proliferation in cancers is not inhibited.
Activity" as used herein relates to a function of the cdk2 protein, and includes the ability of cdk2 to stimulate proliferation or growth by binding to chaperone, or upstream or downstream effecter molecules thereby activating or repressing 20 upstream or downstream pathways which affect proliferation or differentiation.
The term "modulating expression and/or activity" as used herein includes modifying or altering the expression and/or activity of cdk2 protein, compared to unmodified levels of cdk2. Expression and/or activity may be increased or 25 decreased compared to unmodified levels to increase or decrease proliferation or differentiation.
Modulation of cdk2 expression and/or activity in the cell may be achieved using antagonists, inhibitors, mimetics or derivatives of the cdk2 in a direct fashion.
30 The terms "antagonist" or "inhibitor", as used herein, refer to a molecule which, when bound to cdk2, blocks, inhibits or modulates the activity of cdk2.
Antagonists and inhibitors may include proteins, nucleic acids, carbohydrates, antibodies or any other molecules including ligands which bind to cdk2.
Proteins may include enzymes which can degrade cdk2 and therefore affect the
level of cdk2 exposed to the cell. Other modulators of the activity and/or expression of cdk2 include a range of rationally-designed, synthetic inhibitors.
Modulation of cdk2 expression and/or activity may also be achieved by indirect 5 methods. Apart from the direct methods described above, modulation of expression and/or activity of cdk2 may be achieved using direct recombinant methods known to those of skill in the art and include, but are not limited to, knockout technology, antisense technology, triple helix technology, targeted mutation, gene therapy, regulation by agents acting on transcription. Indirect 10 methods for modulating expression and/or activity of cdk2 may include targeting upstream or downstream regulators of cdk-2. More specifically, cdk-inhibitors such as p15, p16, p18, p19, p21, p27 and p57 may be used. Other modulators include other cdk's including cdk4, cam, cdk-7 or cdc25A-C, Wee1-family kineses including Myt1, RB-family proteins pRB, p107 and p130.
Activity of cdk2 can be measured by methods available to the skilled addressee including phosphorylation of substrates such as pRB or indirectly by determining cell proliferation.
20 In a further preferred aspect of the invention, there is provided a method of treating a BRCA associated disorder in a patient, said method comprising administering a therapeutically effective amount of a cdk-2 inhibitor or antagonist to the patient.
25 Preferably the BRCA associated disorder is a BRCA-1 or BRCA-2 disorder and may be any one of the disorders described above. Preferably, the disorder is a BRCA-1 disorder, more preferably, it is a breast cancer.
The cdk-2 inhibitor or antagonist may be administered in any manner which 30 delivers the inhibitor or antagonist to the site to be treated. Carriers which target the cancer cells may be coupled to the inhibitors or antagonists to effectively deliver the compound to the cells of interest.
A therapeutically effective dose as used herein refers to that amount of a compound sufficient to result in a healthful benefit in the treated subject.
Toxicity and therapeutic efficacy may be determined by standard 5 pharmaceutical procedures that may involve cell cultures or experimental animals, e.g., for determining the LD50 tthe dose lethal to 50% of the population) and the EDso (the dose therapeutically effective in 50% of the population). The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of a compound 10 lies preferably within a range of circulating concentrations that include the EDso with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration used in the method of the invention.
15 The inhibitors or antagonists may be formulated into compositions. The compositions can be administered to humans and other animals orally, rectally, parenterally (i.e. intravenously, intramuscularly, or subcutaneously), intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), transdermally, bucally, or as an oral or nasal spray.
The compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and 25 nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of 30 the required particle size in the case of dispersions, and by the use of surfactants. These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of
microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable 5 pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
If desired, and for more effective distribution, the compounds can be incorporated into slow release or targeted delivery systems such as polymer 10 matrices, liposomes, and microspheres.
The injectable formulations can be sterilized, for example, by filtration through a bacterial retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or 15 other sterile injectable medium just prior to use.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier 20 such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca 25 starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, 9) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid 30 polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and
hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
The solid dosage forms of tablets, dragees, capsules, pills, and granules can be 5 prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which 10 can be used include polymeric substances and waxes.
If desired, and for more effective distribution, the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable 20 emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, 25 dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include adjuvants such as 30 wetting agents, emulsifying and suspending agents, sweetening, flavouring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene
sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
Compositions for rectal or vaginal administration are preferably suppositories 5 which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required.
One skilled in the pertinent art will recognize that suitable dosages for any of the modulations described herein will vary, depending upon such factors as the nature of the disorder to be treated, the patient's body weight, age, and general condition, and the route of administration. Preliminary doses can be determined 20 according to animal tests, and the scaling of dosages for human administration is performed according to artaccepted practices.
In yet another aspect of the present invention, there is provided a transgenic animal model for breast cancer wherein said animal shows a clinical interaction 25 between BRCA and p27 said animal comprising a promoter-driven dominant negative BRCA allele.
The tranegenic animal provides a model which replicates an interaction between BRCA and p27. Preferably the model includes a null allele of p27.
The BRCA may be either a BRCA-1 or BRCA-2. Preferably, the BRCAis BRCA-1 and more preferably, the animal expresses a truncated BRCA-1, more preferably comprising amino acids 1-299.
f 15 The BRCA may be promoter driven and any promoter which can induce the expression of BRCA may be used. Preferably, the promoter is an MMTV promoter. S The animals ideally carry null alleles of p27, preferably p27KiP'. This is particularly useful for replicating a loss of p27 which has been shown to be functionally important to the progression of BRCA-1 associated cancers.
The transgenie animal may be any animal, however, mice are particularly 1 0 preferred.
In a further preferred aspect, the transgenic animal contains a p27 allelewhich expresses p27, preferably under the control of a promoter. The animal may be induced via the BRCA-1 allele to show phenotypic characteristics of breast 15 cancer. A promoter driven p27 may be used to reverse phenotypie eharaeteristies of the BRCA-1 allele.
In yet another aspect of the present invention, there is provided a method of screening potential therapeutics for treatment of BRCA associated disorder, 20 said method comprising: inducing a BRCA associated disorder phenotype in a transgenie animal model for the BRCA associated disorder, said animal comprising a promoter driven dominant negative BRCA allele; exposing a potential therapeutic to the transgenie animal; and 25 noting a change in the phenotype.
This method utilizes a transgenic mouse model which substantially reproduces an induction of cancer. In particular, the BRCA associated disorder is a BRCA-
1 gene associated disorder, preferably breast cancer. The breast cancer may 30 arise due to the interaction of BRCA-1 and low p27 levels. Preferably, the transgenic animal carries a null allele of p27 and the BRCA-1 gene can be induced by a suitable promoter such as MMTV. The combination of BRCA-1 and low levels of p27 induces conditions of breast cancer.
The potential therapeutic may be administered to the animal by any route, including but limited to oral, rectal, parenteral, intracisternal, intravaginal, intraperitoneal, topically, transdermal or as an oral or nasal spray.
5 Preferably, the potential therapeutic is a compound which modulates expression and/or activity of cdk2 protein. Preferably, the compound inhibits expression and/or activity of cdk2 protein.
The change in phenotype may be noted physically or by changes in the 10 phenotype or of the change in progression of the breast cancer phenotype.
This may be noted a number of ways including cell proliferation and growth, change a tissue cross section or p27 levels. Preferably, the phenotype is reversed, more preferably p27 levels revert closer to normal levels in the absence of breast cancer. These changes can be compared with animals not 15 exposed to the potential therapeutic.
Examples of the procedures used in the present invention will now be more full described. It should be understood, however, that the following description is
illustrative only and should not be taken in any way as a restriction on the 20 generality of the invention described above.
EXAMPLES
Example 1: Characbrisation of a genetic interaction between brca1 and 25 p27k'P' in the mouse mammary gland.
Breast cancers arising in individuals carrying germline mutations in BRCA1 often display pathological characteristics and a spectrum of secondary genetic mutations that differs from the majority of sporadically derived breast cancers.
30 Several clinical reports show an increased frequency of low expression of the CDK-inhibitor p27KiP, in Brca1-associated cancers, when compared to sporadic cancers.
Mice expressing an MM1V driven C-terminal truncating allele of Brca1 (MMTV-
trBrca1) that is putatively dominant negative over the wild type protein have been generated. Mice expressing MMTV-truncated Brca1 (aa 1-299) were generated at the ICRF transgenic facility. Mice carrying null alleles of p27KiP1 5 were kindly provided by Jim Roberts laboratory (Fero et al, Cell. 1996 May 31;85(5):73344.). Mice are backcrossed at least five generations to the FVB/N strain. Such mice display blunted ductal development of the mammary gland, very 10 similar to the phenotype seen in mice with a mammary specific conditional knockout of Brca1. To investigate the cellular and molecular basis of a genetic interaction between p27KiP' and Brca1, mice expressing the trBrca1 transgene on the background of null alleles of the p27kiP' gene were generated.
15 To conduct histochemistry, mice were injected with 100pg BrdU/gram of body weight 1hr prior to sacrifice. Mammary glands were harvested, whole mounted, fixed in Carnoy's fixative and stained with carmine red or fixed in 10% buffered formalin and embedded in paraffin. Immunohistochemistry was performed on 4p sections using anti-BrdU (BD) or anti-p27 (DAKO). Figure 1 shows reduction in 20 the dosage of p27Kip1 alters the phenotype in MMTV-trBrca1 expressing mice.
Wholemounts of mammary tissue from MMTV-trBrca1 mice gland (B,F) show blunted ductal morphogenesis as virgins and during pregnancy compared to wildtype (A,E) at the same stage (red vs black arrows). p27 deficient mice carrying the transgene (C,G) do not show blunted ductal development (blue vs 25 red arrows), while p27 deficiency alone does not convey a phenotype (D,H).
This interaction is also observed in 42 day old virgins and at day 16.5 of pregnancy (not shown) while approximately 50% of MMTV-trBrca1 p27+/virgin mice show precocious alveolar development (C, blue arrows). Wholemounts are stained with cammine red.
30 Characterisation of mammary development in MMTV-trBrca1 p27KiP'deficient mice are provided.
Figure shows MMTV-trBrca1 and reduced p27 dosage interact during both alveolar development and ductal branching. A. Haemotoxylin and eosin staining
( 18 of day 10 pregnant mammary sections demonstrates the failure of alveolar development in MMTV-trBrca1 compared to wild-type, p27+/- and p27+/-trBrca1 mice. B. Scoring of the number of branch points between nipple and endbud in 70 day old virgin mice demonstrates reduced ductal branching in MMTV-trBrca1 5 mice vs wild-type (*p>0.01). Reduced p27 dosage rescues the branching to wild-type levels.Snap frozen mammary tissue was thawed and Iysed in cyclin E kinase buffer (protein) or Trizol (RNA) using a power homogenizer. Protein was quantitated using a BOA detection method. RNA was quantitated at A260 Figure 3 shows A Reduced dosage of p27 does not reduce the expression of the 10 MMTV-trBrca1 transgene as shown by Northern blot. RNA was probed with the 5' 1kb EcoR1 fragment of the Brca1 cDNA and a Pst1 fragment of GAPDH as loading control. B p27 protein levels are slightly elevated in whole mammary extracts in virgins and at day 10 pregnancy. Results are confounded by disproportionate epithelial content in whole extracts as demonstrated by keratin 15 18 staining.
Figure 4 shows staining for p27Kip1 corresponds to regions with low proliferation, measured by BrdU incorporation. In the ducts, all nuclei are p27 positive (A) while there are c2% BrdU positive cells (C). In the terminal end 20 buds (TEBs) of 42 day old mice, less than half of the cells demonstrate measurable p27 (B) while S-phase is close to 40% (D) in this rapidly proliferating region.
No significant difference in BrdU incorporation is seen between wild-type, 25 MMTV-trBrca1 and p27+/- TEBs, although a trend towards higher S-phase content is seen in p27+/- trBrca1 TEBs (E). Results are average % BrdU positivity (+SD) of at least 5 TEBs from 3 mice, with TEBs identified according to morphological characteristics.Aseptically harvested mammary tissue was finely minced and digested in collagenase. Primary Mammary Epithelial Cells 30 (PMECs) were isolated by differential centrifugation and cultured in defined medium on collagen coated plates. FACs, protein and RNA isolation were performed on cells at passage 2.
Figure 5 shows analysis of primary mammary epithelial cells (PMECs) from transgenic mice. p27Kip1 protein levels are less than 50% wild-type levels in p27+/- mice, while there is a trend towards higher expression in mice with the MMTV-trBrca1 transgene. p21Cip1, cyclin D1 and cyclin E show no significant 5 changes.
These results may provide insight into why BRCA1 associated cancers consistently demonstrate low levels of p27KiP'.
10 These studies show: Reduction in p27Kip1 gene dosage reverses the blunted ductal and alveolar development seen in mice expressing the dominant negative MM7V-trBrca1 gene. We believe that loss of Brca1 function initially confers a cellular 15 disadvantage and that this is overcome on a p27-deficient background.
Our model supports the notion that loss of p27 protein is functionally important to the progression of Brca1-associated cancers although conditions used to culture primary mammary epithelial cells in the short term are not sufficient to 20 replicate the in viva results.
ÀThe mechanism of the in viva interaction is yet to be determined, although we hypothesise that it is due to rescue of an apoptotic phenotype requiring p27Kip1.
Claims (1)
- CLAIMS:1. A method of diagnosis or prognosis of a BRCA associated disorder in a 5 tissue suspected of the disorder, said method comprising determining an interaction between a BRCA gene or gene product and a p27 gene or gene product and comparing the interaction against the interaction in a tissue that is absent the disorder.10 2. A method according to claim 1 wherein the BRCA associated disorder is associated with a disorder of a BRCA-1 or BRCA-2 gene or gene product.3. A method according to claim 1 or 2 wherein the disorder results from a mutation of the BRCA-1 or BRCA-2 gene.4. A method according to any one of claims 1 to 3 wherein the BRCA gene product is selected from the group including a BRCA-1 protein, BAP-1 or BARD1.20 5. A method according to any one of claims 1 to 4 wherein the BRCA associated disorder is selected from lung cancer, gastrointestinal malignancies, breast cancer, prostate cancer, ovarian cancer and carcinomas of the larynx and oral cavity.25 6. A method according to claim 5 wherein the disorder is a breast cancer.7. A method according to any one of claims 1 to 6 wherein the interaction between the BRCA gene or gene product and the p27 gene or gene product is a measure of an increase or decrease of p27 protein.8. A method according to any one of claims 1 to 7 wherein the p27 gene or gene product is a p27kiP' gene or gene product.9. A method according to any one of claims 1 to 8 wherein the interaction between the BRCA gene or gene product and the p27 gene or gene product is an interaction that is modulated by modulating expression and/or activity of a cdk-2 protein.10. A method according to claim 9 wherein the expression and/or activity of the cdk-2 protein is reduced.11. A method according to claim 9 or 10 wherein the expression and/or 10 activity of the cdk2 protein is reduced by a cdk inhibitor or modulator selected from the group including p15, p16, p18, p19, p21, p27, p57, cdk4, cdk-6, cdk-7, cdc25A-C, Wee1-family kineses including Myt1, RB-family proteins pRB, p107 and p130.15 12. A transgenic animal model for breast cancer wherein said animal shows a clinical interaction between BRCA and p27 said animal comprising a promoter-driven dominant negative BRCA allele.13. A transgenic animal according to claim 12 wherein the allele is a null 20 allele of p27.14. A transgenic animal according to claim 13 wherein the null allele of p27 is a p27kiP'.25 15. A transgenic animal according to any one of claims 12 to 14 which expresses a truncated BRCA-1 comprising amino acids 1 to 299 or BRCA-1.16. A method of screening potential therapeutics for treatment of a BRCA associated disorder, said method comprising: 30 inducing a BRCA associated disorder phenotype in a transgenic animal model for the BRCA associated disorder, said animal comprising a promoter driven dominant negative BRCA allele; exposing a potential therapeutic to the transgenic animal; and noting a change in the phenotype.an 17. A method according to claim 16 wherein the BRCA associated disorder is a BRCA-1 gene associated disorder.5 18. A method according to claim 17 wherein the disorder is breast cancer.19. A method according to any one of claims 16 to 18 wherein the disorder is induced by modulating interaction between a BRCA gene or gene product and a p27 gene or gene product.20. A method according to claim 19 wherein induction results from an interaction between BRCA-1 and low levels of p27.21. A method according to any one of claims 16 to 20 wherein the potential 15 therapeutic is a compound which modulates expression and/or activity of cdk-2 protein. 22. A method according to claim 1 substantially as hereinbefore described, with reference to the Example.23. A transgenic animal according to claim 12 substantially as hereinbefore described, with reference to the Example.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPS1659A AUPS165902A0 (en) | 2002-04-10 | 2002-04-10 | Methods of treating brca associated disorder |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0308377D0 GB0308377D0 (en) | 2003-05-14 |
GB2388114A true GB2388114A (en) | 2003-11-05 |
Family
ID=3835236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0308377A Withdrawn GB2388114A (en) | 2002-04-10 | 2003-04-10 | Methods of diagnosis or prognosis of a BRCA associated disorder |
Country Status (3)
Country | Link |
---|---|
US (1) | US20030215861A1 (en) |
AU (1) | AUPS165902A0 (en) |
GB (1) | GB2388114A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008106984A2 (en) * | 2007-03-07 | 2008-09-12 | Aarhus Universitet | Pig model for breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008116347A1 (en) | 2007-03-26 | 2008-10-02 | General Regeneratives Limited | Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies |
US20090170842A1 (en) * | 2007-11-14 | 2009-07-02 | University Of Kansas | Brca1-based breast or ovarian cancer prevention agents and methods of use |
CN104111339B (en) * | 2014-06-26 | 2015-11-25 | 武汉市畜牧兽医科学研究所 | Based on BRCA2 albumen, the mRNA diagnosis of milk cow whether method of gestation and purposes |
-
2002
- 2002-04-10 AU AUPS1659A patent/AUPS165902A0/en not_active Abandoned
-
2003
- 2003-04-10 US US10/410,207 patent/US20030215861A1/en not_active Abandoned
- 2003-04-10 GB GB0308377A patent/GB2388114A/en not_active Withdrawn
Non-Patent Citations (4)
Title |
---|
J. Clin. Oncol., Vol.18, 2000, Chappuis, P. O. et al., "Germline BRCA1/2 mutations...", pp.4045-4052. * |
Jpn. J. Cancer Res., Vol.91, 2000, Niwa, Y. et al., "BRCA1 expression status...", pp.519-526. * |
Proc. Am. Assoc. Cancer Res., Vol.42, 2001, Williamson, E. A. et al., "Brca1 transactivates...", pp.730-731. * |
Proc. Am. Assoc. Cancer Res., Vol.43, March 2002, Deans, A. J. et al., "Characterization of a genetic interaction...", p.992. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008106984A2 (en) * | 2007-03-07 | 2008-09-12 | Aarhus Universitet | Pig model for breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex |
WO2008106984A3 (en) * | 2007-03-07 | 2008-12-31 | Univ Aarhus | Pig model for breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex |
Also Published As
Publication number | Publication date |
---|---|
US20030215861A1 (en) | 2003-11-20 |
GB0308377D0 (en) | 2003-05-14 |
AUPS165902A0 (en) | 2002-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yuan et al. | Elevated NSD3 histone methylation activity drives squamous cell lung cancer | |
Steven et al. | Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target | |
Bisso et al. | Cooperation between MYC and β‐Catenin in liver tumorigenesis requires Yap/Taz | |
Bajenaru et al. | Neurofibromatosis 1 (NF1) heterozygosity results in a cell‐autonomous growth advantage for astrocytes | |
Li et al. | Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations | |
Maroulakou et al. | Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice | |
Akli et al. | Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy | |
Woenckhaus et al. | Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer | |
Zhou et al. | PAX6 suppresses growth of human glioblastoma cells | |
Zheng et al. | Deficiency of the X-inactivation escaping gene KDM5C in clear cell renal cell carcinoma promotes tumorigenicity by reprogramming glycogen metabolism and inhibiting ferroptosis | |
Li et al. | Ubiquitin ligase RNF8 suppresses Notch signaling to regulate mammary development and tumorigenesis | |
Pros et al. | Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors | |
Abdeen et al. | Somatic loss of WWOX is associated with TP53 perturbation in basal-like breast cancer | |
Kosinsky et al. | Usp22 deficiency impairs intestinal epithelial lineage specification in vivo | |
Zhang et al. | Alterations in cell growth and signaling in ErbB3 binding protein-1 (Ebp1) deficient mice | |
Zhou et al. | Brahma‐related gene 1 inhibition prevents liver fibrosis and cholangiocarcinoma by attenuating progenitor expansion | |
Sun et al. | C1GALT1 in health and disease | |
Simigdala et al. | Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer | |
Chew et al. | Targeted disruption of the Lasp-1 gene is linked to increases in histamine-stimulated gastric HCl secretion | |
US20030215861A1 (en) | Methods of treating a BRCA associated disorder | |
Li et al. | Selecting an appropriate experimental animal model for cholangiocarcinoma research | |
US20240082273A1 (en) | Neurokinin inhibitors such as aprepitant for treating non small cell lung carcinoma or breast cancer without mutations | |
AU2003203635A1 (en) | Methods of treating a BRCA associated disorder | |
Long et al. | Uterine deficiency of Dnmt3b impairs decidualization and causes consequent embryo implantation defects | |
Yu et al. | TREM1 facilitates the development of gastric cancer through regulating neutrophil extracellular traps-mediated macrophage polarization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |